Life (Nov 2022)

Biomarkers for Osteoarthritis Diseases

  • Jacob A. Braaten,
  • Mark T. Banovetz,
  • Nicholas N. DePhillipo,
  • Filippo Familiari,
  • Raffaella Russo,
  • Nicholas I. Kennedy,
  • Robert F. LaPrade

DOI
https://doi.org/10.3390/life12111799
Journal volume & issue
Vol. 12, no. 11
p. 1799

Abstract

Read online

Growing evidence has revealed the pivotal role of inflammatory biomarkers in the pathogenesis of osteoarthritis. There is significant interest in the prognostic value of select biomarkers, given the potential for early identification and treatment of patients at risk of osteoarthritis prior to the development of irreversible clinical disease. Clinical trials of novel therapeutics that disrupt the inflammatory pathways of osteoarthritis are also ongoing. The purpose of this review is to summarize the current literature on key biomarkers within the context of osteoarthritis pathogenesis, clinical symptom development, and treatment capabilities. Multiple recent studies have established biomarkers that signal the existence of osteoarthritis pathology and the development of clinical symptomology. However, prior to implementation in clinical practice, additional research is required to precisely define the prognostic value for numerous biomarkers and standardize their measurement. Biomarker-driven investigations represent a promising avenue for the early diagnosis and treatment of osteoarthritis.

Keywords